A fact sheet, slide presentation and videotape that "minimize the potential of Seroquel to cause ocular changes" are among promotions that drew a letter from FDA's ad division May 6. The materials were submitted to FDA following the agency's request in a Nov. 24, 1998, warning letter to review all promotional materials Zeneca continues to distribute. FDA specifically objects to comparisons of Seroquel (quetiapine) and haloperidol and materials emphasizing the use of direct ophthalmoscopy to detect cataract formation. "Direct ophthalmoscopy is not a sensitive measure of lenticular changes and may miss a developing cataract," FDA states. Other violative promotions include a Zeneca brochure implying that the drug is effective for bipolar disorder and schizoaffective disorder. Seroquel is indicated for treatment of manifestations of psychotic disorders in schizophrenic inpatients
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth